Bank of America’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-207,844
| Closed | -$45.9M | – | 5905 |
|
|
2025
Q4 | $45.9M | Sell |
207,844
-33,927
| -14% | -$5.48M | ﹤0.01% | 1616 |
|
|
2025
Q3 | $23.2M | Buy |
241,771
+196,446
| +433% | +$12.5M | ﹤0.01% | 2485 |
|
|
2025
Q2 | $2.21M | Buy |
45,325
+17,824
| +65% | +$428K | ﹤0.01% | 4687 |
|
|
2025
Q1 | $592K | Buy |
27,501
+27,451
| +54,902% | +$610K | ﹤0.01% | 5561 |
|
|
2024
Q4 | $1.34K | Buy |
50
+11
| +28% | +$179 | ﹤0.01% | 7247 |
|
|
2024
Q3 | $419 | Buy |
39
+5
| +15% | +$60 | ﹤0.01% | 7417 |
|
|
2024
Q2 | $406 | Buy |
+34
| New | +$465 | ﹤0.01% | 7392 |
|
|
2024
Q1 | – | Sell |
-3
| Closed | -$42 | – | 7774 |
|
|
2023
Q4 | $42 | Buy |
+3
| New | +$48 | ﹤0.01% | 7525 |
|
|
2023
Q2 | – | Sell |
-36
| Closed | -$919 | – | 7724 |
|
|
2023
Q1 | $919 | Buy |
36
+28
| +350% | +$795 | ﹤0.01% | 7317 |
|
|
2022
Q4 | $114 | Buy |
+8
| New | +$95 | ﹤0.01% | 7646 |
|
|
2022
Q3 | – | Sell |
-1,258
| Closed | -$12K | – | 7856 |
|
|
2022
Q2 | $12K | Sell |
1,258
-454
| -27% | -$5.61K | ﹤0.01% | 7337 |
|
|
2022
Q1 | $28K | Buy |
1,712
+2
| +0.1% | +$34 | ﹤0.01% | 7389 |
|
|
2021
Q4 | $43K | Sell |
1,710
-91
| -5% | -$2.83K | ﹤0.01% | 7274 |
|
|
2021
Q3 | $81K | Sell |
1,801
-288
| -14% | -$10.9K | ﹤0.01% | 6831 |
|
|
2021
Q2 | $84K | Sell |
2,089
-543
| -21% | -$23K | ﹤0.01% | 6603 |
|
|
2021
Q1 | $140K | Buy |
2,632
+2,211
| +525% | +$109K | ﹤0.01% | 6249 |
|
|
2020
Q4 | $17K | Buy |
421
+309
| +276% | +$15.4K | ﹤0.01% | 6621 |
|
|
2020
Q3 | $6K | Sell |
112
-305
| -73% | -$21.5K | ﹤0.01% | 6553 |
|
|
2020
Q2 | $31K | Sell |
417
-786
| -65% | -$50.9K | ﹤0.01% | 6146 |
|
|
2020
Q1 | $60K | Buy |
+1,203
| New | +$72.1K | ﹤0.01% | 5789 |
|
|
2019
Q4 | – | Sell |
-955
| Closed | -$38K | – | 7102 |
|
|
2019
Q3 | $38K | Hold |
955
| – | – | ﹤0.01% | 6408 |
|
|
2019
Q2 | $32K | Sell |
955
-336
| -26% | -$14K | ﹤0.01% | 6452 |
|
|
2019
Q1 | $68K | Sell |
1,291
-8
| -0.6% | -$439 | ﹤0.01% | 6064 |
|
|
2018
Q4 | $61K | Sell |
1,299
-742
| -36% | -$53K | ﹤0.01% | 6135 |
|
|
2018
Q3 | $180K | Buy |
2,041
+20
| +1% | +$1.76K | ﹤0.01% | 5540 |
|
|
2018
Q2 | $210K | Buy |
2,021
+88
| +5% | +$8.31K | ﹤0.01% | 5382 |
|
|
2018
Q1 | $155K | Buy |
+1,933
| New | +$264K | ﹤0.01% | 5508 |
|
|
2017
Q3 | – | Sell |
-198
| Closed | -$30K | – | 7067 |
|
|
2017
Q2 | $30K | Buy |
198
+84
| +74% | +$11.6K | ﹤0.01% | 6079 |
|
|
2017
Q1 | $18K | Buy |
114
+25
| +28% | +$4.39K | ﹤0.01% | 6346 |
|
|
2016
Q4 | $18K | Buy |
89
+55
| +162% | +$11.4K | ﹤0.01% | 6377 |
|
|
2016
Q3 | $8K | Buy |
34
+24
| +240% | +$5.55K | ﹤0.01% | 6454 |
|
|
2016
Q2 | $2K | Buy |
+10
| New | +$2.42K | ﹤0.01% | 6886 |
|
|
2016
Q1 | – | Sell |
-6
| Closed | -$2K | – | 7025 |
|
|
2015
Q4 | $2K | Buy |
6
+5
| +500% | +$1.5K | ﹤0.01% | 7081 |
|
|
2015
Q3 | $0 | Sell |
1
-6
| -86% | -$1.72K | ﹤0.01% | 7226 |
|
|
2015
Q2 | $2K | Buy |
+7
| New | +$2.15K | ﹤0.01% | 7035 |
|
Bank of America's CDTX Position: Q1 2026 in Review
Bank of America sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 207,844 shares — an estimated $45.9M sold.
Bank of America first reported a position in CDTX in Q2 2015 and held it in 35 quarters. The position peaked at $45.9M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Bank of America reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Bank of America sold 207,844 Cidara Therapeutics shares in Q1 2026, an estimated $45.9M.
- Bank of America first reported a position in Cidara Therapeutics in Q2 2015 and held it in 35 quarters.
- Bank of America's Cidara Therapeutics position peaked at $45.9M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.